Bruderman Asset Management LLC Sells 44,735 Shares of Sanofi (SNY)
Bruderman Asset Management LLC lessened its holdings in Sanofi (NYSE:SNY) by 31.0% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 99,702 shares of the company’s stock after selling 44,735 shares during the quarter. Sanofi comprises 1.3% of Bruderman Asset Management LLC’s portfolio, making the stock its 25th largest position. Bruderman Asset Management LLC’s holdings in Sanofi were worth $4,964,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in SNY. Fisher Asset Management LLC grew its holdings in shares of Sanofi by 3.3% during the third quarter. Fisher Asset Management LLC now owns 14,082,257 shares of the company’s stock valued at $701,156,000 after buying an additional 443,799 shares during the last quarter. Founders Financial Securities LLC purchased a new stake in shares of Sanofi during the second quarter valued at approximately $907,000. AMG National Trust Bank grew its holdings in shares of Sanofi by 5.3% during the second quarter. AMG National Trust Bank now owns 51,423 shares of the company’s stock valued at $2,464,000 after buying an additional 2,594 shares during the last quarter. Alethea Capital Management LLC purchased a new stake in shares of Sanofi during the third quarter valued at approximately $794,000. Finally, Parallel Advisors LLC grew its holdings in shares of Sanofi by 42.5% during the second quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock valued at $139,000 after buying an additional 875 shares during the last quarter. Institutional investors and hedge funds own 9.13% of the company’s stock.
A number of research firms have recently commented on SNY. Morgan Stanley cut shares of Sanofi from an “overweight” rating to an “underweight” rating in a report on Friday. Argus reiterated a “buy” rating and set a $55.00 price target on shares of Sanofi in a report on Friday, September 1st. upgraded shares of Sanofi from a “reduce” rating to a “hold” rating in a report on Wednesday, August 30th. BidaskClub upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a report on Saturday, August 5th. Finally, Barclays upgraded shares of Sanofi from an “underweight” rating to an “equal weight” rating in a report on Wednesday, November 15th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $53.50.
Shares of Sanofi (NYSE SNY) traded down $1.02 during trading on Friday, reaching $44.62. 1,767,991 shares of the company were exchanged, compared to its average volume of 1,504,120. The company has a market capitalization of $112,590.00, a P/E ratio of 14.46, a price-to-earnings-growth ratio of 2.53 and a beta of 0.88. Sanofi has a 12 month low of $38.45 and a 12 month high of $50.65. The company has a current ratio of 1.59, a quick ratio of 1.16 and a debt-to-equity ratio of 0.26.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.